Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells

I. Mlynarczuk, G. Hoser, T. Grzela, T. Stoklosa, C. Wójcik, J. Malejczyk, M. Jakóbisiak

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

TRAIL, Tumor necrosis factor-related apoptosis-inducing ligand, a member of the TNF family, is known to be cytotoxic for a high proportion of rumor cell lines. However, successful application of TRAIL in rumor therapy may depend on finding other agents that can potentiate its antitumor effects. The present study showed that the cytostatic/cytotoxic TRAIL activity against U937 cells could be significantly augmented by proteasome inhibitor PSI, as revealed by MTT assay. Increased cytostatic/cytotoxic effect on U937 cells by TRAIL/PSI combined treatment was caused by apoptosis, as shown by an increased PARP cleavage rate. TRAIL/PSI did not affect the level of mRNA expression for TRAIL receptors (DR4, DR5, DcR1) and other apoptosis signal transduction molecules (TRADD, caspase-8).

Original languageEnglish (US)
Pages (from-to)1237-1240
Number of pages4
JournalAnticancer research
Volume21
Issue number2 A
StatePublished - Jun 11 2001

Keywords

  • Apoptosis
  • Proteasome inhibitor
  • TRAIL
  • U937 cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells'. Together they form a unique fingerprint.

  • Cite this

    Mlynarczuk, I., Hoser, G., Grzela, T., Stoklosa, T., Wójcik, C., Malejczyk, J., & Jakóbisiak, M. (2001). Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells. Anticancer research, 21(2 A), 1237-1240.